Clinical Trials Results - National Cancer Institute

In English \| En español

Search


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 80 for your search:

Drug:  imatinib mesylate
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: EUDRACT 2004-001647-30, PHRC/04-04, CIC0203/043, NCT00287105

Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BDE28, NCT00372476

Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: NILG-ALL 10/07, NCT00795756

Phase III Randomized Study of Imatinib Mesylate Alone or With Interferon alfa or Low-Dose Cytarabine Versus Interferon alfa Standard Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: III-MK-CML-IV, EU-20248, NCT00055874

Phase III Randomized Study of Adjuvant Imatinib Mesylate Versus Observation Only in Patients With Completely Resected Localized Gastrointestinal Stromal Tumor at Intermediate- or High-Risk of Relapse

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-62024, ISG-62024, FRE-FNCLCC-EORTC-62024, GEIS-EORTC-62024, EUDRACT-2004-001810-16, NCT00103168

STI571 ProspectIve RandomIzed Trial: SPIRIT

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 030482, NCT00219739

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CSTI571AAT06, NCT00327262

Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 59
Sponsor: Other
Protocol IDs: GRAALL 2005, NCT00327678

Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing c-Kit: Interruption After 5 Years vs Maintenance

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CST1571BFR14, ET2002-021, NCT00367861

10.

Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: SHEBA-06-4015-IH-CTIL, NCT00297570

11.

Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3160A4-3000, NCT00574873

12.

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107DBR01, NCT00751036

13.

Nilotinib Versus Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107A2405, NCT00760877

14.

Phase III, Open-label Study of Nilotinib Versus Imatinib in GIST Patients

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107G2301, NCT00785785

15.

Suboptimal Study Comparing Nilotinib and Imatinib

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107A2404, NCT00802841

16.

Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-intestinal Stromal Tumour

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AB04030, NCT00812240

17.

Phase III Randomized Study of Imatinib Mesylate With Versus Without Surgery to Remove Residual Disease in Patients With Metastatic Gastrointestinal Stromal Tumor That is Responsive to Imatinib Mesylate

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-62063, EORTC-62063, EU-20955, EUDRACT-2007-002257-23, NOVARTIS-EORTC-62063, NCT00956072

18.

Phase II Study of a Non-Myeloablative Conditioning Regimen Comprising Fludarabine and Total Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Imatinib Mesylate, Dasatinib, or Nilotinib-Responsive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Blast Crisis

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: NCI
Protocol IDs: FHCRC-1581.00, 5235, NCI-H02-0087, NCT00036738

19.

Phase I/II Study of Imatinib Mesylate in Patients With Recurrent Oligodendroglioma or Mixed Oligoastrocytoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0272, N0272, NCT00049127

20.

Phase I/II Study of Imatinib Mesylate in Patients With Recurrent or Refractory Aggressive Fibromatosis

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FRE-FNCLCC-SARCOME-05/0401, EU-20515, NCT00287846

21.

Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BIT06, NCT00417807

22.

Phase I/II Pilot Study of Imatinib Mesylate and/or Nilotinib After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: FHCRC-2223.00, 6691, FHCRC-IR-6691, NOVARTIS-FHCRC-2223.00, NCT00702403

23.

First-Line Therapy of Stage IV Colorectal Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AIO KRK 0205, ML20344, NCT00784446

24.

Docetaxel and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NYU 04-47 (H12554), Novartis CSTI571BUS200, NCT00861471

25.

New Individualized Therapy Trial for Metastatic Colorectal Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BUS278T, NCT00867334

Select All on Page

Help with Results

A Service of the National Cancer Institute